Immunic’s (IMUX) Buy Rating Reaffirmed at D. Boral Capital

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $10.00 price target on the stock.

Other research analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. B. Riley reissued a “buy” rating and issued a $5.00 price target (down previously from $6.00) on shares of Immunic in a research note on Friday, May 23rd. William Blair restated an “outperform” rating on shares of Immunic in a research report on Friday, May 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Immunic in a report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $11.60.

Immunic Stock Performance

NASDAQ:IMUX opened at $0.71 on Wednesday. The company has a market cap of $67.84 million, a price-to-earnings ratio of -0.58 and a beta of 1.48. The stock’s fifty day moving average price is $0.92 and its two-hundred day moving average price is $1.01. Immunic has a 52-week low of $0.56 and a 52-week high of $2.11.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.25) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.25). On average, equities analysts predict that Immunic will post -0.94 EPS for the current fiscal year.

Institutional Trading of Immunic

Several hedge funds have recently added to or reduced their stakes in IMUX. 683 Capital Management LLC grew its stake in Immunic by 2.2% in the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock valued at $700,000 after acquiring an additional 15,349 shares during the period. Bridgeway Capital Management LLC grew its position in shares of Immunic by 11.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock valued at $215,000 after purchasing an additional 22,200 shares during the period. Focus Partners Wealth grew its position in shares of Immunic by 1.1% in the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock valued at $2,168,000 after purchasing an additional 23,610 shares during the period. Invesco Ltd. bought a new stake in Immunic during the 4th quarter worth approximately $37,000. Finally, Barclays PLC acquired a new stake in Immunic during the 4th quarter worth approximately $84,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.